return to news
  1. AstraZeneca shares rise 2% on signing LoI with Reliance unit Strand Life Sciences

Market News

AstraZeneca shares rise 2% on signing LoI with Reliance unit Strand Life Sciences

Journalist Kamal Joshi, former Republic TV and latestly news editor, currently associated with Upstox as senior ipo writer.

2 min read | Updated on November 17, 2026, 15:03 IST

SUMMARY

AstraZeneca Pharma India declined 5.36% over the past week and gained 3.27% over the past month. Year-to-date, it fell 29.76%.

Stock list

AstraZeneca Pharma India's market capitalisation stands at ₹15,398.75 crore. | Image: LinkedIn/AstraZeneca

AstraZeneca Pharma India's market capitalisation stands at ₹15,398.75 crore. | Image: LinkedIn/AstraZeneca

Drugmaker AstraZeneca Pharma India Ltd on Tuesday, November 17, said that it has signed a Letter of Intent (LoI) with Reliance Industries subsidiary Strand Life Sciences, which is a genomics research and diagnostics company, to explore opportunities to collaborate in healthcare in India, the company said in an exchange filing.
Open FREE Demat Account within minutes!
Join now

"Through meaningful partnerships, we remain committed to addressing barriers to timely diagnosis and transforming cancer care for patients across India," AstraZeneca said in its LinkedIn handle.

The company and Strand are not related parties. The execution of the LoI does not constitute a related party transaction.

Shares of AstraZeneca Pharma India were trading 2.01% higher at ₹6,154 per share on the National Stock Exchange (NSE) at 2:25 pm.

Its market capitalisation stands at ₹15,398.75 crore.

The scrip declined 5.36% over the past week and gained 3.27% over the past month. Year-to-date, it fell 29.76%.

It had hit its 52-week high of ₹9,469.50 on November 18, 2025, with a year's low of ₹5,640 recorded on October 9, 2026.

AstraZeneca Pharma India Q2 results

The company reported a 14.96% increase in profit after tax to ₹62.33 crore in Q2 FY27, compared to ₹54.22 crore in the year-ago period.

Its revenue from operations climbed 30.41% to ₹729.1 crore in the latest September quarter as against ₹559.09 crore a year back.

The oncology segment contributed 5,085 crore to the revenue, while the biopharmaceutical and rare diseases units posted revenues of 1,610 crore and 204 crore.

Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, said, "The continued growth demonstrates the strength of AstraZeneca’s science-led portfolio and our ability to translate innovation into meaningful impact for patients in India. We are accelerating our efforts across oncology, biopharmaceuticals and rare disease. Our focus remains on building strong partnerships across the healthcare ecosystem to bring innovative medicines to more patients faster and improve health outcomes across the country."

About The Author

Journalist Kamal Joshi, former Republic TV and latestly news editor, currently associated with Upstox as senior ipo writer.
Kamal Joshi is a business journalist who covers markets and IPOs. He places a special focus on in-depth analysis of DRHPs, RHPs and public-issue documents to produce data-driven stories. He covers trends across mainboard and SME IPOs, anchor allocations, subscription status and post-listing performance. He is passionate about breaking news and enjoys playing pickleball, especially flexing his net play. He was previously associated with Republic TV and LatestLY.

Next Story

End of additional stories